Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
AssigneeAbbott Laboratories
InventorsRachael Buck, Geralyn O. Duska-Mcewen, Joseph P. Schaller
Life of this patent
Estimating the term…
Abstract
Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Claims20
A synthetic pediatric formula in powder or liquid form wherein, when the formula is a liquid, the formula comprises:
- a human milk oligosaccharide component comprising a human milk oligosaccharide selected form the group consisting of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof;
- from about 13 mg per 100 kcals to 47 mg per 100 kcals of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
- from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable for at least 3 months.
A synthetic pediatric formula in powder or liquid form wherein, when the formula is a liquid, the formula comprises:
- from about 0.01 mg/mL to about 5 mg/mL of a human milk oligosaccharide component comprising 2′-fucosyllactose and 6′-sialyllactose;
- from about 13 mg per 100 kcals to 47 mg per 100 kcals of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
- from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable from about 3 months to about 24 months.
A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a synthetic pediatric formula comprising:
- a human milk oligosaccharide component comprising a human milk oligosaccharide selected form the group consisting of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof;
- from about 13 mg per 100 kcals to 47 mg per 100 kcals of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
- from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable for at least 3 months.
Dependencies are inferred from the claim text.